Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy

被引：0

作者：

Hiroko Nogi

Akiko Ogiya

Makoto Ishitobi

Chikako Yamauchi

Hiroki Mori

Ayaka Shimo

Kazutaka Narui

Naomi Nagura

Hirohito Seki

Shinsuke Sasada

Teruhisa Sakurai

Tadahiko Shien

机构：

[1] The Jikei University School of Medicine,Department of Breast and Endocrine Surgery

[2] Cancer Institute Hospital,Department of Breast Surgical Oncology

[3] Japanese Foundation for Cancer Research,Department of Breast Surgery

[4] Japanese Red Cross Medical Center,Department of Breast Surgery

[5] Mie University School of Medicine,Department of Radiation Oncology

[6] Shiga General Hospital,Department of Plastic and Reconstructive Surgery

[7] Tokyo Medical and Dental University,Department of Breast and Endocrine Surgery

[8] St. Marianna University School of Medicine,Department of Breast and Thyroid Surgery, Medical Center

[9] Yokohama City University,Department of Breast Surgical Oncology

[10] St Luke’s International Hospital,Department of Breast Surgery

[11] Kyorin University School of Medicine,Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine

[12] Hiroshima University,Department of Breast and Endocrine Surgery

[13] Sakurai Breast Clinic,undefined

[14] Okayama University Hospital,undefined

来源：

Breast Cancer | 2024年 / 31卷

关键词：

Breast cancer; Neoadjuvant chemotherapy; Immediate breast reconstruction; Postoperative complications; Locoregional recurrence;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：507 / 518

页数：11

共 155 条

[1]

Arnold M(2022)Current and future burden of breast cancer: Global statistics for 2020 and 2040 Breast 66 15-23

[2]

Morgan E(1993)Preoperative chemotherapy in operable breast cancer Lancet 341 1485-1235

[3]

Rumgay H(2021)Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 Ann Oncol 32 1216-774

[4]

Mafra A(2022)Systemic therapy for early-stage breast cancer: learning from the past to build the future Nat Rev Clin Oncol 19 763-628

[5]

Singh D(2019)Trastuzumab Emtansine for residual invasive HER2-positive breast cancer N Engl J Med 380 617-2159

[6]

Laversanne M(2017)Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med 376 2147-1268

[7]

Bonadonna G(2022)Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Ann Oncol 33 1250-90

[8]

Valagussa P(2023)Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Lancet Oncol 24 77-84

[9]

Brambilla C(2021)Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial Lancet Oncol 22 74-1028

[10]

Ferrari LG(2000)The psychological impact of immediate rather than delayed breast reconstruction Eur J Surg Oncol 26 17-2451

← 1 2 3 4 5 6 7 8 9 10 →